Receptor Biologix
Receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases
About Receptor Biologix
Receptor BioLogix, Inc. operated as a biopharmaceutical company focused on developing biological therapeutics for cancer and other complex diseases. Founded in 2003 with an exclusive technology license from Oregon Health Sciences University, the company was established by Michael Shepard, Ph.D., a scientist known for his contributions to the development of Herceptin®. The firm's primary business was centered on drug discovery and development, specifically targeting the human EGF receptor (HER) family of pathways, which are dysregulated in many solid cancers.
The company's core technology revolved around two main platforms. The first was the development of "Hermodulins," also known as pan-HER ligand traps. These were engineered fusion proteins designed to block the various ligands that stimulate tumor growth by inhibiting the compensatory feedback mechanisms that often limit the effectiveness of other cancer drugs. This approach showed significant anti-cancer potential in preclinical studies. The second platform was its Intron Fusion Protein (IFP™) technology, aimed at discovering new, naturally occurring forms of human proteins with therapeutic potential. In July 2006, the company expanded its pipeline by acquiring the assets of Aphton Corp., including the therapeutic cancer vaccine Insegia, which was studied for gastrointestinal cancers.
Throughout its operation, Receptor BioLogix was a privately held entity, funded by venture capital. Its investors included Domain Associates, EW Healthcare Partners, MedImmune Ventures, and New Science Ventures. The company went through several leadership changes, with Thomas A. Glaze appointed CEO in 2006, followed by Dale R. Pfost, Ph.D., in late 2008. This final CEO appointment coincided with an additional $6 million financing round to advance the pan-HER program. The company's journey culminated on January 29, 2009, when its technology and programs were acquired by the Danish biopharmaceutical company Symphogen A/S, which specialized in recombinant polyclonal antibodies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2005 | $34M | $134M | Essex Woodlands Health Ventures · Domain Associates · Northwest Technology Ventures · Skyline Ventures | — |
| SEED✓Equity / VC | Jun 2003 | $40K | $160K | Takeda Ventures | — |
Growth signals
Latest recorded traffic for Receptor Biologix is 0 monthly website visits. Receptor Biologix's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Receptor Biologix in the Palo Alto ecosystem
The Receptor Biologix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Takeda Ventures
Series A5 investors entered at this stage
Essex Woodlands Health Ventures
Domain Associates- NVNorthwest Technology Ventures
Skyline Ventures
MedImmune Ventures
Other known investors1 additional known investor
EW Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Receptor Biologix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Receptor Biologix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








